Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis - 24/04/21
, Satoshi Yasuda, MD, PhD b, c, Koichi Kaikita, MD, PhD d, Junya Ako, MD, PhD e, Tetsuya Matoba, MD, PhD f, Masato Nakamura, MD, PhD g, Katsumi Miyauchi, MD, PhD h, Nobuhisa Hagiwara, MD, PhD i, Kazuo Kimura, MD, PhD j, Atsushi Hirayama, MD, PhD k, Kunihiko Matsui, MD, MPH l, Hisao Ogawa, MD, PhD c, 1Highlights |
• | Sub-analysis of AFIRE trial according to patient risk of stroke and bleeding. |
• | Consistent efficacy and safety of rivaroxaban monotherapy across all risk levels. |
• | Modest performance of risk scores for predicting stroke and bleeding. |
Riassunto |
Background |
In the AFIRE trial, rivaroxaban monotherapy was noninferior to combination therapy with rivaroxaban and an antiplatelet agent for thromboembolic events or death, and superior for major bleeding in patients with atrial fibrillation (AF) and stable coronary artery disease. Little is known about impacts of stroke and bleeding risks on the efficacy and safety of rivaroxaban monotherapy.
Methods |
In this subanalysis of the AFIRE trial, we assessed the risk of stroke and bleeding by the CHADS2, CHA2DS2-VASc, and HAS-BLED scores. The primary efficacy end point was the composite of stroke, systemic embolism, myocardial infarction (MI), unstable angina requiring revascularization, or death from any cause. The primary safety end point was major bleeding defined by the International Society on Thrombosis and Haemostasis.
Results |
Rivaroxaban monotherapy significantly reduced the primary efficacy and safety end points with no evidence of differential effects by stroke risk (CHADS2, p for interaction = 0.727 for efficacy, 0.395 for safety; CHA2DS2-VASc, p for interaction = 0.740 for efficacy, 0.265 for safety) or bleeding risk (HAS-BLED, p for interaction = 0.581 for efficacy, 0.225 for safety). There was also no evidence of statistical heterogeneity across patient risk categories for other end points; stroke or systemic embolism, ischemic stroke, hemorrhagic stroke, MI, MI or unstable angina, death from any cause, any bleeding, or net adverse clinical events.
Conclusions |
The advantages of rivaroxaban monotherapy compared with those of combination therapy with respect to all prespecified end points, including thromboembolism, bleeding, and mortality were similar across patients with AF and stable coronary artery disease, irrespective of their risk for stroke and bleeding.
Clinical Trial Registration |
UMIN Clinical Trials Registry number, UMIN000016612, and ClinicalTrials.gov number, NCT02642419.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 236
P. 59-68 - giugno 2021 Ritorno al numero
Articolo precedente
- Does study subject diversity influence cardiology research site performance?: Insights from 2 U.S. National Coronary Stent Registries
- Wayne B. Batchelor, Abdulla A. Damluji, Celina Yong, Mona Fiuzat, Scott D. Barnett, David E. Kandzari, Matthew W. Sherwood, Kelly C. Epps, Behnam N. Tehrani, Dominic J. Allocco, Ian T. Meredith, JoAnn Lindenfeld, Christopher M. O'Connor, Roxana Mehran
- Total vascular resistance increases during volume-unloading in asymptomatic single ventricle patients
- Danish Vaiyani, Kumiyo Matsuo, Usama Kanaan, Bhavesh Patel, Ololade Akintoye, Curtis D Travers, Michael Kelleman, Ritu Sachdeva, Christopher J Petit
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?